Table 3.
Surface modification of dental implants with peptides
| Author | Animal – bone site | Surface modification | Length of study | Findings |
|---|---|---|---|---|
| Germanier et al. [40] | Pig – maxilla | 1. SLA (control) 2. SLA + PLL-g-PEG 3. SLA + PLL-g-PEG/PEG-RDG 4. SLA + PLL-g-PEG/PEG-RGD |
2 and 4 weeks | % of BIC - SLA: 43.6% at 2 weeks, 62.5% at 4 weeks - SLA + PLL-g-PEG: 55.9% at 2 weeks, 67.4% at 4 weeks - SLA + PLL-g-PEG/PEG-RDG: 48.5% at 2 weeks, 75.5% at 4 weeks - SLA + PLL-g-PEG/PEG-RGD: 61.7% at 2 weeks, 62.5% at 4 weeks |
| Barros et al. [41] | Dog – mandible | 1. A: microstructured + HA + low concentrated (20 μg/ml) peptide 2. B: microstructured + HA 3. C: microstructured 4. D: microstructured + HA + high concentrated (200 μg/ml) peptide |
12 weeks | % of BIC - A: 60.4% - B: 62.4% - C: 58.0% - D: 65.4% BD - A: 54.7% - B: 46.0% - C: 45.3% - D: 40.7% |
| Yang et al. [42] | Rabbit – femur and tibia | 1. Control: uncoated 2. RGD-coated |
4, 8, and 12 weeks | % of BIC - Control: 50.2%, 58.5%, and 60.9% at 4, 8, and 12 weeks, respectively - RGD-coated: 70.0%, 74.9%, and 82.2% at 4, 8, and 12 weeks, respectively |
| Lutz et al. [43] | Pig – forehead | 1. Group A: HA 2. Group B: HA + P-15 (20 μg/ml) 3. Group C: HA + P-15 (200 μg/ml) |
14 and 30 days | % of BIC for ROI A and ROI B, respectively - A: 63.8 & 76.7% at 14 days, 70.9 & 75.8% at 30 days - B: 72.1 & 72.5% at 14 days, 69.9 & 74.6% at 30 days - C: 88.2 & 88.7% at 14 days, 80.5 & 88.5% at 30 days BD for ROI A and ROI B, respectively - A: 49.5 & 36.2% at 14 days, 38.4 & 28.7% at 30 days - B: 44.0 & 31.6% at 14 days, 45.7 & 42.9% at 30 days - C: 44.9 & 36.1% at 14 days, 47.2 & 44.5% at 30 days |
| Yoo et al. [44] | Rabbit - tibia | 1. Anodized Ti implant (control) 2. PLGA/rhBMP-2 coated |
3 and 7 weeks | % of BIC (total) - Control: 27.26% at 3 weeks; 31.47% at 7 weeks - PLGA/rhBMP-2: 34.69% at 3 weeks; 35.32% at 7 weeks |
SLA sandblasted and acid-etched surface; PLL-g-PEG poly(L-lysine)-graft-poly(ethylene glycol); RDG Arg-Asp-Gly; RGD Arg-Gly-Asp; BIC bone to implant contact; BD bone density; HA hydroxyapatite; P-15 P-15 peptide; ROI region of interest